The increase in CD38 triggered by tinostamustine seems to be, at least in part, transcriptionally regulated, since in three out of the four evaluated myeloma cell lines (JJN3, MM.1S and RPMI-8226), CD38 mRNA levels were upregulated after treatment with tinostamustine. Here, CD38 is linked to plasma cell myeloma.